Peptide for site-specific antibody conjugation and method of use
The peptide DCAYHLGELXWCT enables site-specific conjugation of antibodies, addressing the challenges of random binding and impaired performance in traditional methods, by forming covalent bonds with the Fc domain, ensuring precise and effective labeling and multiplexed analysis.
Patent Information
- Application Number
- PCT/IB2024/054780
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2024-05-17
- Publication Date
- 2024-11-28
AI Technical Summary
Traditional methods for conjugating antibodies to detection molecules result in random binding sites, impairing antibody performance and potentially leading to non-specific binding, as they are difficult to predict and can alter the antibody's conformation.
A peptide with the amino acid sequence DCAYHLGELXWCT, where X is para-benzoyl phenylalanine, is used to form a covalent bond with the Fc domain of antibodies, allowing for site-specific conjugation of detection molecules or oligonucleotides, using UV light and click reactions, enabling precise labeling and multiplexing.
This method provides a way to specifically link detection molecules or oligonucleotides to antibodies, maintaining their affinity and conformation, allowing for precise identification of antigens and enabling multiplexed analysis of multiple antibodies in a sample.
Smart Images

Figure IB2024054780_28112024_PF_FP_ABST
Abstract
Description
[0001] PEPTIDE FOR SITE-SPECIFIC ANTIBODY CONJUGATION
[0002] AND METHOD OF USE
[0003] CROSS-REFERENCING
[0004] This application claims the benefit of U.S. provisional application serial no. 63 / 469,016, filed on May 25, 2023, which application is incorporated by reference in its entirety.
[0005] INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED AS A SEQUENCE LISTING XML FILE
[0006] A Sequence Listing is provided herewith as a Sequence Listing XML, “PIXL-008WO_SEQLIST”, created on May 16, 2024, and having a size of 11,036 bytes. The contents of the Sequence Listing XML are incorporated herein by reference in their entirety.
[0007] BACKGROUND
[0008] Antibodies can be conjugated to detection molecules for a variety of research and diagnostics applications. The sites to which the detection molecules bind may be either random or site-specific. Chemistries that result in random conjugates include, for example, NHS ester-based methods. In these methods, NHS ester-coupled labels become linked to primary amines at one or more sites on the antibody surface. The exact number and positions of the sites that become labeled using NHS ester chemistry is often difficult to predict and depends on the sequence and structure of the antibody. In addition, traditional coupling methods may impair antibody performance. For example, traditional labeling methods may decrease the affinity of an antibody for its target or even alter the conformation of the antibody which may, in turn, cause the antibody to bind to other targets non-specifically. Alternative solutions are therefore needed.
[0009] SUMMARY
[0010] Provided herein is a peptide comprising the amino acid sequence DCAYHLGELXW CT (SEQ ID NO: 1), wherein X is para-benzoyl phenylalanine (pBPA) and the peptide is 13- 17 amino acids in length. In some embodiments, the peptide may further comprise a C terminal linker, e.g., a polyethylene glycol (PEG) linker that can terminate in a click reactive group, e.g., an azide group. In some embodiments, the linker may be coupled to another moiety such as an oligonucleotide, e.g., via a triazole linkage (which is the covalent bond produced by a click reaction). In these embodiments, the oligonucleotide may comprise a nucleic acid barcode that identifies an antibody. In any embodiment, the peptide may have a disulfide bond between the Cys residues at positions 2 and 12 of SEQ ID NO: 1. This bond cyclizes the peptide.
[0011] In some embodiments, the peptide may be used to link a moiety such as a drug (e.g., a cytotoxic agent) or a detectable label (e.g., a radioisotope, an enzyme which generates a detectable product, a fluorescent protein, a fluorophore, or the like) to an antibody. In these embodiments, the drug or detectable label may be conjugated to the peptide (often via a linker) prior to coupling with the antibody.
[0012] Also provided is a method for covalently linking the peptide to the Fc domain of an antibody. In some embodiments, this method may comprise combining the peptide with an antibody that has an Fc domain to produce a mix, and irradiating the mix with uv light (e.g., light having a wavelength in the range of 320 nm to 380 nm) to covalently link the peptide to the Fc domain of the antibody. In these embodiments, the pBPA of the peptide reacts with the Fc domain of antibody to form a covalent linkage. In any embodiment, the peptide may be coupled to an oligonucleotide. In these embodiments, the method provides a way to link an oligonucleotide to an antibody. In these embodiments, the oligonucleotide may comprise a nucleic acid barcode that identifies an antibody such that the target for the antigen (i.e., the antigen to which it binds) can be determined by analysis of the sequence of the oligonucleotide that is conjugated to the antibody. In other embodiments, the method provides a way to link a moiety such as a drug or detectable agent to the antibody.
[0013] Also provided is a method for joining the peptide to moiety such as an oligonucleotide, drug or detection agent. These embodiments may comprise combining a click-reactive peptide with an moiety that contains a terminal click-reactive group to produce a mix and incubating the mix to covalently link the peptide to the moiety.
[0014] In any embodiment, the antibody may be an IgG antibody modified to abolish its ability to bind to the FC receptor (i.e., FcyR). This may be done making the following amino acid substitutions in the antibody: E234A E235A P329G.
[0015] A variety of kits are also provided. In some embodiments, a kit may comprise a click reactive peptide and a corresponding click-reactive oligonucleotide, where the peptide and oligonucleotide can become covalently bound to one another via a click reaction. In other embodiments, a kit may comprise a peptide and an antibody that comprises an Fc domain. In some of these embodiments, the oligonucleotide may comprise a nucleic acid barcode that identifies an antibody such that the target for the antigen (i.e., the antigen to which it binds) can be determined by analysis of the sequence of the oligonucleotide that is conjugated to the antibody.
[0016] BRIEF DESCRIPTION OF THE FIGURES
[0017] The skilled artisan will understand that the drawings, described below, are for illustration purposes only. The drawings are not intended to limit the scope of the present teachings in any way.
[0018] Fig. 1 is an SDS-PAGE gel showing conjugation of the PGN5 peptide to an anti-CD3 antibody that has a rabbit IgG Fc. The antibody is not coupled to the conjugate in lane 2. The antibody is coupled to the conjugate in lane 3.
[0019] Fig. 2 is an SDS-PAGE gel showing conjugation of other peptides to the anti-CD3 antibody that has a rabbit IgG Fc
[0020] Fig. 3 is an SDS-PAGE gel showing rabbit isotype control IgG (Abeam) conjugation to PGNl.
[0021] Fig. 4. is an SDS-PAGE gel showing a human IgGl Fc (LA / LA / PG) anti-CD3 conjugation. Lane 10: unconjugated antibody. Lane 11 shows the conjugate.
[0022] DEFINITIONS
[0023] Unless defined otherwise herein, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described.
[0024] All patents and publications, including all sequences disclosed within such patents and publications, referred to herein are expressly incorporated by reference. Numeric ranges are inclusive of the numbers defining the range. Unless otherwise indicated, nucleic acids are written left to right in 5' to 3' orientation; amino acid sequences are written left to right in amino to carboxy orientation, respectively.
[0025] The headings provided herein are not limitations of the various aspects or embodiments of the invention. Accordingly, the terms defined immediately below are more fully defined by reference to the specification as a whole.
[0026] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 2D ED., John Wiley and Sons, New York (1994), and Hale & Markham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, N.Y. (1991) provide one of skill with the general meaning of many of the terms used herein. Still, certain terms are defined below for the sake of clarity and ease of reference.
[0027] As used herein, the term “labeling” refers to binding antibodies to specific sites in a sample (i.e., sites that contain an antigen for the antibodies being used). Methods for binding antibodies and aptamers to sites in the sample are well known. As would be apparent, labeling requires incubating the sample and conjugates under conditions (which conditions include a period of time, a temperature, an appropriate binding buffer and a wash) that are suitable for specific binding of the antibodies to molecules (e.g., epitopes) in the sample sample.
[0028] As used herein, the term "primary antibody" refers to an antibody that recognizes antigens that are native to a biological sample. Such antibodies are typically monoclonal antibodies, e.g., mouse or rabbit monoclonal antibodies that recognize human antigens. In any embodiment, the peptide described here may be conjugated to an antibody that is used as a primary antibody.
[0029] As used herein, the term "antibody-oligonucleotide conjugate" refers to a conjugate between an antibody and an oligonucleotide.
[0030] The term “oligonucleotide” as used herein denotes a single-stranded multimer of nucleotides of from about 2 to 200 nucleotides, up to 500 nucleotides in length. Oligonucleotides may be synthetic or may be made enzymatically, and, in some embodiments, are 30 to 150 nucleotides in length. Oligonucleotides may contain ribonucleotide monomers (i.e., may be oligoribonucleotides) or deoxyribonucleotide monomers. An oligonucleotide may be 10 to 20, 21 to 30, 31 to 40, 41 to 50, 51to 60, 61 to 70, 71 to 80, 80 to 100, 100 to 150 or 150 to 200 nucleotides in length, for example.
[0031] The terms “plurality”, “set” and “population” are used interchangeably to refer to something that contains at least 2 members. In certain cases, a plurality may have at least 10, at least 100, at least 1000, at least 10,000, or at least 100,000 members.
[0032] The term “sequencing”, as used herein, refers to a method by which the identity of at least 10 consecutive nucleotides (e.g., the identity of at least 20, at least 50, at least 100 or at least 200 or more consecutive nucleotides) of a polynucleotide are obtained.
[0033] Other definitions of terms may appear throughout the specification.
[0034] DETAILED DESCRIPTION
[0035] As summarized above, provided herein is a peptide comprising the amino acid sequence DCAYHLGELXWCT (SEQ ID NO: 1), wherein X is para-benzoyl phenylalanine (pBPA) and the peptide is 13-17 amino acids in length (e.g., 13, 14, 15, 16 or 17 amino acids in length). X is counted as an amino acid in this peptide, since para-benzoyl phenylalanine is a phenylalanine derivative. In its cyclic form (which is created by a disulfide bond between the cystines at positions 2 and 12), the peptide is capable of specifically binding to and forming a covalent bond with the Fc domain of a human, mouse or rabbit IgG antibody (among others) by exposure to uv light.
[0036] The peptide may be synthetically made and, as such, may contain a variety of modifications, e.g., a C terminal linker such as a polyethylene glycol (PEG) linker. In some embodiments, the linker may terminate in a click reactive group (i.e., a group that is capable of participating in a “click” reaction (see, e.g., Evans et al, Aus. J. Chem. 2007 60 : 384- 395)) such as an azide group or an alkyl group. In other embodiments, the peptide may already be coupled to another moiety (e.g., an oligonucleotide) via the linker. In these embodiments, the other moiety may be coupled to the linker via a click reaction, in which case the conjugate may contain a triazole linkage (which is the bond produced by a click reaction). As will be described in greater detail below, if the peptide is coupled to an oligonucleotide, then the oligonucleotide may comprise a nucleic acid sequence (a 'barcode' sequence) that identifies an antibody. Disulfides can be induced by any suitable method, e.g., exposing the peptide to oxidizing conditions.
[0037] In some embodiments, the peptide may be coupled to a drug (e.g., a cytotoxic moiety such as an anti-microtubule agent, an alkylating agent, or a DNA minor groove binding agents) or a detectable agent such as a fluorescent dye (e.g., fluorescein isothiocyanate, texas red, rhodamine, a green fluorescent protein, a red fluorescent protein, a yellow fluorescent protein, or the like), a radiolabels (e.g., 3H, 1251, 35S, 14C, or 32P), an enzyme (e.g., horse radish peroxidase, alkaline phosphatase, luciferase, and others commonly used in an enzyme-linked immunosorbent assay (ELISA)), a colorimetric label or a contrast agent.
[0038] In any embodiment, the antibody may be an IgG antibody modified to abolish its ability to bind to the FC receptor (i.e., FcyR). This may be done making the following amino acid substitutions in the antibody: L234A L235A P329G (which may be referred to as LA / LA / PG).
[0039] As noted above, the peptide is capable of specifically binding to and forming a covalent bond with the Fc domain of a human, mouse or rabbit IgG antibody (among others) by exposure to uv light. This method may comprise combining the peptide with an antibody that has an Fc domain to produce a mix and irradiating the mix with light having a wavelength in the range of 320 to 380nm. The uv light causes the peptide to covalently link to the Fc domain of the antibody. In embodiments in which the peptide is coupled to an oligonucleotide, the oligonucleotide may comprise a nucleic acid sequence (a 'barcode' sequence) that identifies an antibody. In other words, the sequence of the oligonucleotide that is conjugated to an antibody may uniquely identify the antibody and / or the antigen to which the antibody binds. Such barcoding allows antibodies to be multiplexed. For example, some downstream analysis methods may be performed using 10 different antibodies. In these embodiments, each of the antibodies may be tethered to a different oligonucleotide that contains a sequence that identifies the target to which the antibody binds. This feature allows the method to be multiplexed and, in some embodiments, at least 5, at least 10, at least 20 or at least 50 different antibodies that bind to different targets (which may be on the surface of a cell or in a tissue sample, etc.) can be used in the method. Each antibody may be conjugated to a different antibody identification sequence, and the antibody identification sequences allows the binding events for a particular antibody to be identified.
[0040] The antibody-oligonucleotide conjugates described above may be used to label a biological sample using a method that may comprise (a) labeling the biological sample with one or more of the antibody-oligonucleotide conjugates to produce a labeled sample; (b) optionally cross-linking the antibodies to the sample using a cross-linker or by incubating the labeled sample with a secondary antibody that recognizes the antibody of the antibody- oligonucleotide conjugates (as described in 63 / 414,883, filed on October 10, 2022); (c) performing one or more molecular reactions on the oligonucleotide of the antibody- oligonucleotide conjugates to produce a nucleic acid product; and (d) detecting the nucleic acid product of (c). In these embodiments, the barcoding provides a way to perform the method using multiple antibodies, which method comprises en masse labeling a biological sample with a plurality of antibody-oligonucleotide conjugates that recognize different targets in or on the sample (where the term "en masse" is intended to mean at the same time), and then detecting a binding pattern using a method that uses DNA sequencing.
[0041] For example, the sample may be labeled with at least 10 or at least 20 and up to 50 or 100 or more antibodies, each linked to a different oligonucleotide that identifies the antibody to which it is conjugated. In these embodiments, the detecting step may comprise sequencing at least the antibody identifier sequences in the nucleic acid reaction product, thereby identifying the antibodies that are bound to the sample. Molecular reactions that may be employed in this method include, for example, hybridization, ligation, primer extension, or gap-fill ligation, or any combination thereof. For example, the molecular reaction may comprise a hybridization with a nucleic acid followed by a primer extension and / or gap-fill ligation reaction using the either the oligonucleotide or the nucleic acid as a template. In other embodiments, the molecular reaction of may be a ligation, e.g., a splinted ligation. In some embodiments, a molecular reaction of may be a proximity assay, e.g., proximity ligation reaction (e.g., PLA) or a proximity extension reaction (e.g., PEA). In any embodiment, the method may be used in the types of spatial assays described in WO / 2022 / 208327, the descriptions of which assays are incorporated by reference herein.
[0042] In multiplexed embodiments, the oligonucleotide of a conjugate comprises an antibody identifier sequence (a barcode) that uniquely identifies the primary antibody to which it is conjugated. In these embodiments, the method may comprise en masse labeling the biological sample with a plurality of the antibody-oligonucleotide conjugates that recognize different targets in or on the sample; and sequencing at least the antibody identifier sequences in a nucleic acid reaction product.
[0043] In some embodiments, an oligonucleotide may be added to the peptide. This method may comprise combining a peptide that has a click reactive group such as an azide with an oligonucleotide that contains a terminal click reactive group e.g., an alkyne such as a dibenzylcyclooctyne (DBCO) group, to produce a mix and incubating the mix to covalently link the peptide to the oligonucleotide via a click reaction.
[0044] A variety of kids are also provided. The components of the kit may be in separate containers that are contained within the same packaging (e.g., a box). In some embodiments, the kit may contain a peptide that has a click reactive group and i. a click-reactive oligonucleotide and / or ii. an antibody that comprises an Fc. In some embodiments, the kit may comprise the peptide, the click-reactive oligonucleotide; and the antibody that comprises an Fc. In these embodiments, the oligonucleotide may comprise a nucleic acid barcode that identifies the antibody. In some embodiments, the kit may comprises the peptide, a plurality of (e.g., at least 1, at least 20, at least 30, at least 40, at least 50) oligonucleotides that comprises a nucleic acid barcode, and a corresponding plurality of antibodies, wherein the oligonucleotides comprises nucleic acid barcodes that uniquely only one of the antibodies.
[0045] The antibody-oligonucleotide conjugates described herein find general use in a wide variety of application for analysis of a sample (e.g., in the analysis of tissue sections, sheets of cells, spun-down cells, cell suspensions, blood cells, etc.).
[0046] In any embodiment, the biological sample comprises cells. For example, the biological sample can be a cell suspension, a piece of tissue, or cells mounted on a microscope slide (e.g., an FFPE section). Sample include cultured cells that have been grown as a cell suspension, disassociated cells (which cells may have been produced by disassociating cultured cells or cells that are in a solid tissue, e.g., a soft tissue such as liver of spleen, using trypsin or the like). In particular embodiments, the complexes may be immobilized on cells that can be found in blood, e.g., cells that in whole blood or a subpopulation of cells thereof. Sub-populations of cells in whole blood include platelets, red blood cells (erythrocytes), and white blood cells (i.e., peripheral blood leukocytes, which are made up of neutrophils, lymphocytes, eosinophils, basophils and monocytes). These five types of white blood cells can be further divided into two groups, granulocytes (which are also known as polymorphonuclear leukocytes and include neutrophils, eosinophils and basophils) and mononuclear leukocytes (which include monocytes and lymphocytes). Lymphocytes can be further divided into T cells, B cells and NK cells. Peripheral blood cells are found in the circulating pool of blood and not sequestered within the lymphatic system, spleen, liver, or bone marrow. If cells that are immobilized on a support are used, then then the sample may be made by, e.g., growing cells on a planar surface, depositing cells on a planar surface, e.g., by centrifugation, by cutting a three dimensional object that contains cells into sections and mounting the sections onto a planar surface, i.e., producing a tissue section. In any embodiments, the cells may be fixed but not permeabilized. In any embodiment, the cells used in the method may be free cells (i.e., cells that are not attached to a substrate or each other that in in a suspension, e.g., blood cells) that have been fixed (e.g., using a fixative such as PF A) but not permeabilized. Specifically, the cells may be blood cells that have been fixed using, e.g., PFA, but not treated with a detergent or any other permeabilization agent.
[0047] In certain embodiments, one or more of the antibodies may specifically bind to biomarkers, including cancer biomarkers, that may be proteinaceous, e.g., cell surface markers. Exemplary cancer biomarkers, include, but are not limited to carcinoembryonic antigen (for identification of adenocarcinomas), cytokeratins (for identification of carcinomas but may also be expressed in some sarcomas), CD 15 and CD30 (for Hodgkin's disease), alpha fetoprotein (for yolk sac tumors and hepatocellular carcinoma), CD117 (for gastrointestinal stromal tumors), CD10 (for renal cell carcinoma and acute lymphoblastic leukemia), prostate specific antigen (for prostate cancer), estrogens and progesterone (for tumour identification), CD20 (for identification of B-cell lymphomas) and CD3 (for identification of T-cell lymphomas).
[0048] The above-described method can be used to analyze cells from a subject to determine, for example, whether the cell is normal or not or to determine whether the cells are responding to a treatment. In one embodiment, the method may be employed to determine the degree of dysplasia in cancer cells. In these embodiments, the cells may be a sample from a multicellular organism.
[0049] The method described above finds particular utility in examining samples using a plurality of antibodies, each antibodies recognizing a different marker. Examples of cancers, and biomarkers that can be used to identify those cancers, are shown below. In these embodiments, one does not need to examine all of the markers listed below.
[0050] The compositions and methods described herein can be used to diagnose a patient with a disease. In some cases, the presence or absence of a biomarker in the patient’s sample can indicate that the patient has a particular disease (e.g., cancer). In some cases, a patient can be diagnosed with a disease by comparing a sample from the patient with a sample from a healthy control. In this example, a level of a biomarker, relative to the control, can be measured. A difference in the level of a biomarker in the patient’s sample relative to the control can be indicative of disease. In some cases, one or more biomarkers are analyzed in order to diagnose a patient with a disease. The compositions and methods of the disclosure are particularly suited to identifying the presence or absence of, or determining expression levels, of a plurality of biomarkers in a sample.
[0051] In some cases, the compositions and methods herein can be used to determine a treatment plan for a patient. The presence or absence of a biomarker may indicate that a patient is responsive to or refractory to a particular therapy. For example, a presence or absence of one or more biomarkers may indicate that a disease is refractory to a specific therapy and an alternative therapy can be administered. In some cases, a patient is currently receiving the therapy and the presence or absence of one or more biomarkers may indicate that the therapy is no longer effective.
[0052] In any embodiment, data can be forwarded to a “remote location”, where “remote location,” means a location other than the location at which the data produced by the method is examined. For example, a remote location could be another location (e.g., office, lab, etc.) in the same city, another location in a different city, another location in a different state, another location in a different country, etc. As such, when one item is indicated as being "remote" from another, what is meant is that the two items can be in the same room but separated, or at least in different rooms or different buildings, and can be at least one mile, ten miles, or at least one hundred miles apart. "Communicating" information references transmitting the data representing that information as electrical signals over a suitable communication channel (e.g., a private or public network). "Forwarding" an item refers to any means of getting that item from one location to the next, whether by physically transporting that item or otherwise (where that is possible) and includes, at least in the case of data, physically transporting a medium carrying the data or communicating the data. Examples of communicating media include radio or infra-red transmission channels as well as a network connection to another computer or networked device, and the internet or including email transmissions and information recorded on websites and the like. In certain embodiments, the data may be analyzed by an MD or other qualified medical professional, and a report based on the results of the analysis of the data may be forwarded to the patient from which the sample was obtained.
[0053] In some cases, the method may be employed in a variety of diagnostic, drug discovery, and research applications that include, but are not limited to, diagnosis or monitoring of a disease or condition (where the data identifies a marker for the disease or condition), discovery of drug targets (where the a marker in the data may be targeted for drug therapy), drug screening (where the effects of a drug are monitored by a marker shown in the data ), determining drug susceptibility (where drug susceptibility is associated with a marker) and basic research (where is it desirable to measure the differences between cells in a sample).
[0054] In certain embodiments, two different samples may be compared using the above methods. The different samples may be composed of an “experimental” sample, i.e., a sample of interest, and a “control” sample to which the experimental sample may be compared. In many embodiments, the different samples are pairs of cell types or fractions thereof, one cell type being a cell type of interest, e.g., an abnormal cell, and the other a control, e.g., normal, cell. If two fractions of cells are compared, the fractions are usually the same fraction from each of the two cells. In certain embodiments, however, two fractions of the same cell may be compared. Exemplary cell type pairs include, for example, cells isolated from a tissue biopsy (e.g., from a tissue having a disease such as colon, breast, prostate, lung, skin cancer, or infected with a pathogen etc.) and normal cells from the same tissue, usually from the same patient; cells grown in tissue culture that are immortal (e.g., cells with a proliferative mutation or an immortalizing transgene), infected with a pathogen, or treated (e.g., with environmental or chemical agents such as peptides, hormones, altered temperature, growth condition, physical stress, cellular transformation, etc.), and a normal cell (e.g., a cell that is otherwise identical to the experimental cell except that it is not immortal, infected, or treated, etc.); a cell isolated from a mammal with a cancer, a disease, a geriatric mammal, or a mammal exposed to a condition, and a cell from a mammal of the same species, preferably from the same family, that is healthy or young; and differentiated cells and non-differentiated cells from the same mammal (e.g., one cell being the progenitor of the other in a mammal, for example). In one embodiment, cells of different types, e.g., neuronal and non-neuronal cells, or cells of different status (e.g., before and after a stimulus on the cells) may be employed. In another embodiment of the invention, the experimental material is cells susceptible to infection by a pathogen such as a virus, e.g., human immunodeficiency virus (HIV), etc., and the control material is cells resistant to infection by the pathogen. In another embodiment, the sample pair is represented by undifferentiated cells, e.g., stem cells, and differentiated cells.
[0055] Cells any organism, e.g., from bacteria, yeast, plants and animals, such as fish, birds, reptiles, amphibians and mammals may be used in the subject methods. In certain embodiments, mammalian cells, i.e., cells from mice, rabbits, primates, or humans, or cultured derivatives thereof, may be used.
[0056] The following publications are incorporated by reference for all purposes: US9365619B2, US20200397912, EP3719031A2, Von Witting et al (Bioconjugate Chem. 2021 32: 1515-1524, Park et al (Bioconjugate Chem. 2018 29: 3240-3244) and Vane et al (Bioconjugate Chem. 2019 30: 148-160).
[0057] EXAMPLES
[0058] The following examples are put forth so as to provide those of ordinary skill in the art with additional disclosure and description of how to make and use the present invention, and are not intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed.
[0059] EXAMPLE 1
[0060] PGN5 and five variants (PGN1-4 and 'Park') were tested for their ability to couple with rabbit IgG. The sequences of these peptides are shown below. '(BPA)' is a para-benzoyl phenylalanine (pBPA) residue in these sequences.
[0061] DCAYHLGEL(BPA)WCT PGN1 SEQ ID NO: 1
[0062] DCAWHRGEL(BPA)WCT PGN2 SEQ ID NO: 2
[0063] DCAWHIGEL(BPA)WCT PGN3 SEQ ID NO: 3
[0064] DC A YHRGEL(B PA) WCT PGN4 SEQ ID NO: 4 GPDCAYHRGEE(BPA)WCTFH PGN5 SEQ ID NO: 5
[0065] DCAWHLGEL(BPA)WCT Park SEQ ID NO: 6 were tested for their ability to couple to rabbit IgG.
[0066] These peptides were chemically synthesized with azido-PEG2 linker at the C- terminus. Disulfide bonds between the cysteines were introduced post synthesis to cyclize the peptide and a DNA oligonucleotide of 75 bases carrying a 3’-DBC0 alkyne was first coupled to the peptide at +4 °C overnight.
[0067] This conjugate was mixed in surplus with a rabbit IgG antibody that has an Fc region that comprises the LA / LA / PG amino acid substitutions and placed on ice for 4 hours under UV to evaluate their coupling to the IgG. Products were run on a gel and quantified.
[0068] Results are shown in the table below:
[0069] The PGN5 peptide / oligonucleotide conjugate coupled to Rabbit IgG but with a significant amount of unconjugated antibody remaining, 64%.
[0070] The PGN 1 peptide performed well with only 31 % unconjugated antibody.
[0071] Fig. 1 shows the results for PGN5.
[0072] Fig. 2 shows the results for PGN5PGN1-4 and the Park peptide.
[0073] The PGN 1 peptide was selected for further study.
[0074] PGN1 was tested for its ability to couple to bulk rabbit IgG (Abeam). Results are shown in Table 2 and Figure 3.
[0075] Table 2: Conjugations made to rabbit isotype control IgG (Abeam)
[0076] Finally, PGN1 was tested for its ability to couple to human IgGl. This data shows that PGN1 couples to human IgGl with good efficiency of only 26% free antibody. See Table 3 and Fig. 4.
[0077] Table 3. Conjugation made to anti-CD3 human IgGl Fc (LA / LA / PG)
[0078] The sequences of the rabbit and human antibodies used in these experiments are shown below.
[0079] Sequence of rabbit Fc IgGl (LA / LA / PG) (SEQ ID NO: 7):
[0080] GQPKAPSVFPLAPCCGDTPSSTVTLGCLVKGYLPEPVTVTWNSGTL
[0081] TNGVRTFPSVRQSSGLYSLSSVVSVTSSSQPVTCNVAHPATNTKVD
[0082] KTVAPSTCSKPTCPPPEAAGGPSVFIFPPKPKDTLMISRTPEVTCVV
[0083] VDVSEDDPEVQFTWYINNEQVRTARPPLREQQFNSTIRVVSTLPIA
[0084] HEDWLRGKEFKCKVHNKALGAPIEKTISKARGQPLEPKVYTMGPP
[0085] REELSSRSVSLTCMINGFYPSDISVEWEKNGKAEDNYKTTPAVLDS
[0086] DGSYFLYSKLSVPTSEWQRGDVFTCSVMHEALHNHYTQKSISRSP
[0087] GK
[0088] Sequence of human Fc IgGl (LA / LA / PG) (SEQ ID NO: 8):
[0089] ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGAL
[0090] TSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNT
[0091] KVDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR
[0092] TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST
[0093] YRVVSVLTVLHQDWLNGKEYKCKVSNKALGAPIEKTISKAKGQP
[0094] REPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPE
[0095] NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL
[0096] HNHYTQKSLSLSPGK
Claims
CLAIMSWhat is claimed is:
1. A peptide comprising the amino acid sequence DC AYHLGELXWCT (SEQ ID NO: 1), wherein:X is para-benzoyl phenylalanine (pBPA) and the peptide is 13-17 amino acids in length.
2. The peptide of claim 1, further comprising a C terminal linker.
3. The peptide of claim 2, wherein the linker is polyethylene glycol (PEG).
4. The peptide of claim 3, wherein the peptide comprises a C terminal PEG linker that terminates in a click reactive group.
5. The peptide of claim 3, wherein the peptide comprises a C terminal PEG linker that terminates in an azide group.
6. The peptide of claim 2 or 3, wherein the linker is coupled to an oligonucleotide or other moiety via triazole linkage.
7. The peptide of claim 2 or 3, wherein the linker is coupled to a drug or detectable agent.
8. The peptide of claim 6, wherein the linker is coupled to an oligonucleotide and the oligonucleotide comprises a nucleic acid barcode that identifies an antibody.
9. The peptide of any prior claim, wherein the peptide has a disulfide between the Cys residues at positions 2 and 12 of SEQ ID NO: 1.
10. A method comprising: combining the peptide of any of claims 1-9 with an antibody that has an Fc domain toproduce a mix; and irradiating the mix with light having a wavelength in the range of 320 to 380nm, to covalently link the peptide to the Fc domain of the antibody to make a conjugate.
11. The method of claim 10, wherein the peptide is coupled to an oligonucleotide or other moiety.
12. The method of claim 11, wherein the peptide is coupled to an oligonucleotide comprising a nucleic acid barcode that identifies an antibody.
13. The method of claim 11, wherein the peptide is coupled to a drug or detectable agent.
14. The method of any of claims 11-13, further comprising:(a) labeling the biological sample with one or more of the antibody-oligonucleotide conjugates to produce a labeled sample;(b) optionally cross-linking the antibody and producing a cross-linked sample;(c) performing one or more molecular reactions on the oligonucleotide of the antibody-oligonucleotide conjugates to produce a nucleic acid product; and(d) detecting the nucleic acid product of (c).
15. The method of claim 14, wherein the oligonucleotide of a conjugate comprises an antibody identifier sequence that uniquely identifies the antibody to which it is conjugated.
16. The method of claim 15, wherein: step (a) comprises en masse labeling the biological sample with a plurality of antibody-oligonucleotide conjugates that recognize different targets in or on the sample; and step (d) comprises sequencing at least the antibody identifier sequences in the nucleic acid reaction product of (c).
17. The method of any of claims 14-16, wherein the molecular reaction of (c) is a hybridization, ligation, primer extension, or gap fill, or any combination thereof.
18. A method comprising :combining the peptide of any of claims 4-5 with a moiety that contains a click reactive group to produce a mix; and incubating the mix to covalently link the peptide to the moiety.
19. The method of claim 18, wherein the moiety is an oligonucleotide, drug or detectable agent.
20. A kit comprising a peptide of any of claims 4-5 and i. a click-reactive moiety such as an oligonucleotide; and / or ii. an antibody that comprises an Fc.
21. The kit of claim 20, comprising the peptide, the click-reactive oligonucleotide; and the antibody that comprises an Fc, wherein the oligonucleotide comprises a nucleic acid barcode that identifies the antibody.
22. The kit of claim 21, wherein the kit comprises the peptide, a plurality of oligonucleotides that comprises a nucleic acid barcode, and a corresponding plurality of antibodies, wherein the oligonucleotides comprises nucleic acid barcodes that uniquely only one of the antibodies.
Citation Information
Patent Citations
Method for conjugating antibody and physiologically active substance
EP3719031A2
Method for conjugating antibody and physiologically active substance
US20200397912A1
IgG-binding peptide and method for detecting and purifying IgG using same
US9365619B2
Spatial mapping by serial primer extension
WO2022208327A1
Adsorbent columns using antibody Fc―binding peptide
KR101609840B1
